<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-JUFPTGZA</identifier><date>2020</date><creator>Božič, Tajda</creator><creator>Hanžel, Jurij</creator><creator>Janša, Rado</creator><creator>Štabuc, Borut</creator><relation>documents/doc/J/URN_NBN_SI_doc-JUFPTGZA_001.pdf</relation><relation>documents/doc/J/URN_NBN_SI_doc-JUFPTGZA_001.txt</relation><format format_type="issue">2</format><format format_type="volume">54</format><format format_type="type">article</format><format format_type="extent">str. 233-236, XI</format><identifier identifier_type="DOI">10.2478/raon-2020-0027</identifier><identifier identifier_type="ISSN">1318-2099</identifier><identifier identifier_type="COBISSID">19073283</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-JUFPTGZA</identifier><language>eng</language><publisher>Association of Radiology and Oncology</publisher><source>Radiology and oncology (Ljubljana)</source><rights>BY</rights><subject language_type_id="slv">hepatocelularni karcinom</subject><subject language_type_id="slv">preživetje</subject><subject language_type_id="slv">sorafenib</subject><title>a single-centre real-world study</title><title>Sorafenib for the treatment of hepatocellular carcinoma</title></Record>